Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia

Autor:	Jennifer R. Brown, Philip C. Amrein, Philippe Armand, Jacob D. Soumerai, Lillian Werner, Ephraim P. Hochberg, Jeremy S. Abramson, Donna Neuberg, David C. Fisher, Matthew S. Davids
Rok vydání:	2019
Předmět:	Bendamustine Oncology Male Cancer Research medicine.medical_specialty Chronic lymphocytic leukemia Drug Administration Schedule 03 medical and health sciences 0302 clinical medicine immune system diseases hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Bendamustine Hydrochloride Humans neoplasms Lenalidomide Aged Neoplasm Staging business.industry Remission Induction Hematology Middle Aged medicine.disease Prognosis Leukemia Lymphocytic Chronic B-Cell Treatment Outcome 030220 oncology & carcinogenesis Rituximab Female business Standard therapy 030215 immunology medicine.drug
Zdroj:	Leukemialymphoma. 60(12)
ISSN:	1029-2403
Popis:	Bendamustine-rituximab (BR) is a standard therapy in CLL, and lenalidomide has single-agent activity. This phase 1 study evaluated lenalidomide-BR as initial CLL therapy. Thirteen patients were treated at three dose levels (DL), and an additional 10 were treated at the MTD. The MTD was DL3: lenalidomide 5 mg daily D8-21 of C1, then 10 mg D1-21 of C2-6. One DLT occurred at DL2 (pulmonary embolus). Grade ≥3 toxicities included neutropenia (52.2%), rash (26.1%), anemia (21.7%), thrombocytopenia (21.7%), and febrile neutropenia (13.0%). Of 13, 9 treated at the MTD required dose modification, most for neutropenia (5). OR and CR rates were 87% and 39%, respectively. Lenalidomide-BR could be safely administered and was active as initial CLL therapy, although frequent dose modification at the MTD suggests that lenalidomide 10 mg is too high for most patients. Given the current treatment landscape, lenalidomide combinations warrant evaluation in CLL patients who are chemonaïve but have been failed by the approved targeted therapies.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e98a9a1ac91590284757a4fac483633 https://pubmed.ncbi.nlm.nih.gov/31074316 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.